The anticancer potential of chemical constituents of Moringa oleifera targeting CDK-2 inhibition in estrogen receptor positive breast cancer using in-silico and in vitro approches
Most of the breast cancers are estrogen receptor-positive recurring with a steady rate of up to 20 years dysregulating the normal cell cycle. Dinaciclib is still in clinical trials and considered as a research...
Source: BMC Complementary and Alternative Medicine - Category: Complementary Medicine Authors: Rida Sultan, Abrar Ahmed, Li Wei, Hamid Saeed, Muhammad Islam and Muhammad Ishaq Tags: Research Source Type: research